Photodynamic Diagnosis in Non-Muscle-Invasive Bladder Cancer

European Urology, Supplements

Volumn 9, Issue 3, 2010, Pages 411-418

  Bordier, Benoit ^a   Mazerolles, Catherine ^a   Malavaud, Bernard ^a  

^a CHU RANGUEIL   (France)

Author keywords

Carcinoma in situ; Hexyl amino levulinate; Non muscle invasive bladder cancer; Photodynamic diagnosis

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; BCG VACCINE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HEME; MITOMYCIN C; PROTEIN P53; PROTOPORPHYRIN;

ANGIOGENESIS; BLADDER; BLADDER CANCER; BLUE LIGHT; CANCER CELL; CANCER DIAGNOSIS; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL TRIAL; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FALSE POSITIVE RESULT; FLUORESCENCE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; HYPERPLASIA; NARROW BAND IMAGING; NONMUSCLE INVASIVE BLADDER CANCER; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMICS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN METABOLISM; RAMAN SPECTROMETRY; RECURRENCE RISK; REVIEW; SIGNAL NOISE RATIO; TRANSURETHRAL RESECTION; WHITE LIGHT ENDOSCOPY;

EID: 77950520173     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2010.02.007     Document Type: Review

References (22)

1. Ferlay J., Randi G., Bosetti C., et al. Declining mortality from bladder cancer in Europe. BJU Int 101 (2008) 11-19
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225-249
3. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477 discussion 475-7
4. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
5. Svanberg K., af Klinteberg C., Nilsson A., et al. Laser-based spectroscopic methods in tissue characterization. Ann NY Acad Sci 838 (1998) 123-129
6. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
7. Singh M., and Fulvio J.M. Visual extrapolation of contour geometry. Proc Natl Acad Sci U S A 102 (2005) 939-944
8. Igarashi T., Suzuki H., and Naya Y. Computer-based endoscopic image-processing technology for endourology and laparoscopic surgery. Int J Urol 16 (2009) 533-543
9. Cauberg E.C.C., de Bruin D.M., Faber D.J., van Leeuwen T.G., de la Rosette J.J.M.C.H., and de Reijke T.M. A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. Eur Urol 56 (2009) 287-297
10. Burger M., Zaak D., Stief C.G., et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 52 (2007) 142-147
11. Steinbach P., Weingandt H., Baumgartner R., et al. Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. Photochem Photobiol 62 (1995) 887-895
12. Jichlinski P., Guillou L., Karlsen S.J., et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 170 (2003) 226-229
13. Kausch I., Sommerauer M., Montorsi F., et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 57 (2010) 595-606
14. Billerey C., Chopin D., Aubriot-Lorton M.H., et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158 (2001) 1955-1959
15. Van Rhijn B.W., van der Kwast T.H., Vis A.N., et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64 (2004) 1911-1914
16. Stenzl A., Roessler W., Fradet Y., et al. Hexvix fluorescence cystoscopy improves detection and resection of papillary bladder cancer. Eur Urol Suppl 8 (2009) Abstract 1010
17. Sievert K.D., Amend B., Nagele U., et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol 27 (2009) 295-300
18. McKenney J.K., Gomez J.A., Desai S., Lee M.W., and Amin M.B. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol 25 (2001) 356-362
19. Herr H.W., Donat S.M., and Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?. J Urol 177 (2007) 75-79 discussion 79
20. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU Int. In press.
21. Mostofi FK, Sobin LH, Torloni H. Epithelial tumors. Histological typing of urinary bladder tumors. In: WHO series manual, Volume 10. Geneva, Switzerland: World Health Organisation 1973;21-31.
22. Sauter G., Algaba F., Amin M., et al. Tumors of the urinary sytem: non-invasive urothelial neoplasias. In: Eble J.N., Sauter G., Epstein J.I., and Sesterhenn I. (Eds). WHO classification of tumors of the urinary system and male genital organs (2004), IARCC Press, Lyon, France 110-123